Health and Fitness Health and Fitness
Wed, January 16, 2013
Tue, January 15, 2013
Mon, January 14, 2013
Fri, January 11, 2013
Thu, January 10, 2013
Wed, January 9, 2013
Tue, January 8, 2013
[ Tue, Jan 08th 2013 ] - Market Wire
Cambridge Heart Provides Update
Mon, January 7, 2013
Sun, January 6, 2013
Fri, January 4, 2013
Thu, January 3, 2013
Wed, January 2, 2013
Mon, December 31, 2012
Fri, December 28, 2012
[ Fri, Dec 28th 2012 ] - Market Wire
Verisante Issues Stock Options
Thu, December 27, 2012
Wed, December 26, 2012
[ Wed, Dec 26th 2012 ] - Market Wire
30 p.m. ET
Mon, December 24, 2012
Fri, December 21, 2012
Thu, December 20, 2012
[ Thu, Dec 20th 2012 ] - Market Wire
A View from the Top
Wed, December 19, 2012
Tue, December 18, 2012
Mon, December 17, 2012
Fri, December 14, 2012
Thu, December 13, 2012

Jazz Pharmaceuticals to Webcast Presentation at J.P. Morgan Healthcare Conference


//health-fitness.news-articles.net/content/2013/ .. ntation-at-j-p-morgan-healthcare-conference.html
Published in Health and Fitness on Wednesday, January 2nd 2013 at 14:00 GMT by Market Wire   Print publication without navigation


Jazz Pharmaceuticals to Webcast Presentation at J.P. Morgan Healthcare Conference -- DUBLIN, Jan. 2, 2013 /PRNewswire/ --

DUBLIN, Jan. 2, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: [ JAZZ ]) announced today that the company will webcast its presentation at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2013. The webcast is scheduled to begin at 10:00 a.m. PST (6:00 p.m. GMT).  Bruce Cozadd , chairman and chief executive officer of Jazz Pharmaceuticals, will present an overview of the company and provide a business and financial update.

The webcast can be accessed from the Investors section of the Jazz Pharmaceuticals website at [ www.jazzpharmaceuticals.com ].  An archived version of the webcast will be available at the same location for at least one week following the presentation.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Luvox CR® (fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its international division, EUSA Pharma. For further information, see [ www.jazzpharmaceuticals.com ].

SOURCE Jazz Pharmaceuticals plc



RELATED LINKS
[ http://www.jazzpharma.com ]

Publication Contributing Sources